Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 264 participants.
Also called NCT03437226
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 264 participants
- Registry
-
NCT03437226
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Austria
- Registry status
- Unknown status
Technical summary
Registry record NCT03437226. Randomized; triple masking; primary purpose treatment. Start 2018-03-08 (actual); primary completion 2019-04-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure
- Acronym
- LeoDOR
- Condition
- Heart Failure
- Intervention (Drug)
- Levosimendan 2.5 MG/ML
- Intervention (Drug)
- Placebos
- Lead sponsor
- Dr. Gerhard Pölzl
- Collaborator
- Orion Corporation, Orion Pharma
Record details
- Record id
cardio:ct-nct03437226- Content hash
082c94a8ee1a13763f3d296e83939798b007679fa5699d80b426c7f6f4ca9154